Try our Advanced Search for more refined results

In re HIV Antitrust Litigation

Track this case

Case Number:

3:19-cv-02573

See also:

Court:

California Northern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action

Judge:

Edward M Chen

Firms

Companies

Government Agencies

Sectors & Industries:

  1. June 07, 2023

    Teva Atty Says Gilead Deal Followed Bad News On FDA Filing

    A top Teva lawyer testified Wednesday in an antitrust trial over claims that the company struck an illegal "pay for delay" deal with Gilead over two HIV medications, saying Teva reached the mid-trial settlement just days after learning the FDA was unlikely to give it first-filer rights to exclusively sell its generic versions.

  2. June 06, 2023

    Ex-Gilead GC Says He Didn't Calculate Teva's Gain In IP Deal

    Gilead's ex-general counsel testified Tuesday in a "pay for delay" antitrust trial over its HIV drug patent deal with Teva, saying he never calculated a dollar value for the royalty-free license Gilead gave Teva, which ultimately gave Teva six months on the generics market ahead of competitors.

  3. June 05, 2023

    Ex-Gilead VP Says Execs Gamed Out Truvada Generic Date

    A former Gilead executive testifying Monday in an antitrust trial over claims Gilead and Teva illegally delayed generic versions of its blockbuster HIV drugs until 2020 told jurors that before the pharmaceutical makers' deal, Gilead executives discussed the possibility that generic competition for Truvada could come as early as 2017.

  4. May 30, 2023

    Teva's Drug IP Deal With Gilead Not Pay To Delay, Jurors Hear

    Teva's counsel defended the generic-drug maker Tuesday during opening statements in a California trial over claims it reached an anticompetitive deal with Gilead over two HIV medications, saying it settled a patent suit brought by Gilead because it risked losing, not to score an illegal "pay for delay" deal.

  5. May 25, 2023

    Gilead, Teva Ink 11th-Hour HIV Antitrust Deal With Pharmacies

    With openings set to begin Thursday in an antitrust trial over claims Gilead and Teva illegally inflated HIV drug prices, the two drugmakers struck a last-minute deal with major pharmacies, and Gilead settled with direct purchasers — leaving indirect purchasers and others to take their claims to a California federal jury.

  6. May 24, 2023

    Jurors Weren't Barred Over Race, Gilead Antitrust Judge Says

    A California federal judge overseeing an antitrust trial over claims that Gilead and Teva inflated HIV drug prices has rebuffed the pharmaceutical giants' Batson challenge alleging that the plaintiffs had improperly sought to exclude Asian jurors, noting that several Asian Pacific Islanders were picked for the jury.

  7. May 23, 2023

    HIV Drug Antitrust Trial 'Leaving The Station,' Judge Says

    A California federal judge who has pressed for a settlement in a sprawling litigation over claims Gilead and Teva inflated HIV drug prices told the parties on Tuesday that the trial would go forward on Wednesday, saying, "The train is leaving the station."

  8. May 10, 2023

    Lack Of HIV Drug Deal Before Trial Shocks Antitrust Judge

    A California federal judge on Wednesday urged parties to settle in the sprawling certified consumer antitrust class action alleging that Gilead, Janssen and Teva inflated HIV drug prices, saying that trying the case has "huge risks" and "Frankly, I'm not only disappointed, I'm astounded" the parties had not yet settled.

  9. April 19, 2023

    Gilead, Janssen, Teva Can't Say HIV Drug Costs Passed On

    Health care insurers going to trial next month in their suit against Gilead, Janssen and Teva won't have to worry about arguments they passed on any overcharges after a California federal judge banned the drugmakers from using that defense in the sprawling certified consumer antitrust class action alleging drugmakers artificially inflated HIV drug prices.

  10. February 21, 2023

    Gilead, Janssen And Teva Face HIV Drug Antitrust Trial In May

    A California federal judge has unveiled his reasoning for mostly refusing to hand either side a clear-cut summary judgment victory in the sprawling certified consumer antitrust class action alleging that Gilead, Janssen and other drugmakers artificially inflated HIV drug prices, teeing up the high-stakes dispute for a May jury trial.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!